Fennec Pharmaceuticals Inc. (FENCF) 2.3686 $FENCF Fennec

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Fennec Pharmaceuticals Inc. (FENCF) 2.3686 $FENCF

Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting
PR Newswire - Mon Jun 01, 10:00AM CDT
Fennec Pharmaceuticals, Inc. (TSX: FRX, OTCQB: FENCF), announced the presentation of positive interim results from a poster presented today entitled, "Anti-tumor efficacy in SIOPEL6: A multi-centre open label randomised phase III trial of the efficacy of sodium thiosulphate (STS) in reducing ototoxicity in patients receiving cisplatin (Cis) monotherapy for standard risk hepatoblastoma (SR-HB)." The data was presented at the American Society of Clinical Oncology (ASCO) 2015 Annual Meeting in Chicago. The poster is available today on the website http://fennecpharma.com/investors/presentations-events/.
FRX.TO: 2.77 (-0.29)

Fennec Announces Presentation of Positive Interim Sodium Thiosulfate Phase III Safety Data at the 2015 ASCO Annual Meeting
Marketwired - Sun May 31, 8:01PM CDT
Fennec Pharmaceuticals, Inc. (TSX: FRX) (OTCQB: FENCF), announced the presentation of positive interim results from a poster presented today entitled, "Anti-tumor efficacy in SIOPEL6: A multi-centre open label randomised phase III trial of the efficacy of sodium thiosulphate (STS) in reducing ototoxicity in patients receiving cisplatin (Cis) monotherapy for standard risk hepatoblastoma (SR-HB)." The data was presented at the American Society of Clinical Oncology (ASCO) 2015 Annual Meeting in Chicago. The poster is available today on the website http://fennecpharma.com/investors/presentations-events/.
FRX.TO: 2.77 (-0.29)

Fennec to Present at the Jefferies 2015 Global Healthcare Conference
Marketwired - Fri May 29, 5:01AM CDT
Fennec Pharmaceuticals Inc. (TSX: FRX)(OTCQB: FENCF) today announced that it will present at the Jefferies 2015 Global Healthcare Conference being held in New York City. Rosty Raykov, CEO, will provide an overview of the Company's business on Tuesday, June 2, 2015 at 11:30 a.m. (ET).
FRX.TO: 2.77 (-0.29)

Fennec Announces Results of Annual Meeting
Marketwired - Thu May 28, 7:29PM CDT
Fennec Pharmaceuticals Inc. (TSX: FRX)(OTCQB: FENCF) today announced that the nominees listed in the management proxy circular dated April 23, 2015 (the "Circular" for the Annual Meeting of Shareholders were elected as directors of the Company at the Annual Meeting of Shareholders held in Durham, North Carolina on May 28, 2015 (the "Meeting" . Detailed results of the vote for the election of directors are set out below:
FRX.TO: 2.77 (-0.29)

Fennec Provides Corporate Update and First Quarter Ended March 31, 2015 Financial Results
Marketwired - Fri May 15, 6:01AM CDT
Fennec Pharmaceuticals Inc. (TSX: FRX)(OTCQB: FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric patients, today reported its corporate developments and financial results for the first quarter ended March 31, 2015.
FRX.TO: 2.77 (-0.29)

Fennec Announces Availability of Siopel 6 Study Abstract for ASCO 2015 Meeting
Marketwired - Thu May 14, 5:01AM CDT
Fennec Pharmaceuticals, Inc. (TSX: FRX)(OTCQB: FENCF), today announced that sodium thiosulfate (STS) will be featured in the abstract titled "Anti-tumor efficacy in SIOPEL6: A multi-centre open label randomised phase III trial of the efficacy of sodium thiosulphate (STS) in reducing ototoxicity in patients receiving cisplatin (Cis) monotherapy for standard risk hepatoblastoma (SR-HB)." at the American Society of Clinical Oncology (ASCO) being held May 29 through June 2, 2014 in Chicago, IL. The abstract is available as of today on the website http://www.abstract.asco.org/.
FRX.TO: 2.77 (-0.29)

Fennec Pharmaceuticals Announces the Exercise of Warrants by the Company's Largest Shareholder and Provides Updated Corporate Capital Structure
Marketwire Canada - Mon May 04, 6:17AM CDT
Fennec Pharmaceuticals, Inc. (TSX:FRX)(OTCQB:FENCF), today reported that Southpoint Master Fund, LP ("Southpoint" , the Company's largest shareholder with 36.6% of Fennec's issued and outstanding shares has exercised 0.3 million warrants at a price of USD$1.50. Net proceeds from the exercise of the warrants are expected to be approximately USD$0.45 million to the Company. Further, 1.3 million warrants at a price of CAD$4.32 expired on April 30, 2015.
FRX.TO: 2.77 (-0.29)

Southpoint Files Early Warning Report in Connection With Exercise of Warrants in Fennec Pharmaceuticals Inc.
Marketwired - Wed Apr 29, 12:32PM CDT
Southpoint Master Fund, LP ("Southpoint" has acquired, by the exercise of 293,511 warrants of Fennec Pharmaceuticals Inc. ("Fennec" at an exercise price of USD$1.50 per warrant (which represents approximately CAD$1.80 per warrant, based on the Bank of Canada's noon rate of USD$1 = CAD$1.2021 on April 28, 2015), 293,511 common shares of Fennec (the "Transaction" . The shares acquired pursuant to the Transaction represent approximately 2.8% of the issued and outstanding common shares of Fennec. The common shares were issued from Fennec's treasury.

Fennec Pharmaceuticals Provides Corporate Update and Fiscal Year Ended December 31, 2014 Financial Results
Marketwired - Wed Apr 01, 6:31AM CDT
Fennec Pharmaceuticals Inc. (TSX: FRX)(OTCQB: FENCF), a clinical stage biopharmaceutical company focused on the development of sodium thiosulfate (STS) for the prevention of ototoxicity from cisplatin in pediatric patients, today reported its corporate update and financial results for the year ended December 31, 2014. All amounts are in US dollars unless otherwise specified.
FRX.TO: 2.77 (-0.29)

Fennec Pharmaceuticals Announces That the Independent Data Monitoring Committee (IDMC) Recommends the Continuation of SIOPEL 6 Phase 3 Clinical Trial
Marketwired - Mon Feb 02, 7:02AM CST
Fennec Pharmaceuticals Inc. (TSX: FRX)(OTCQB: FENCF), a company focused on the development of sodium thiosulfate (STS) for the prevention of ototoxicity from cisplatin in pediatric patients, announced that the IDMC overseeing the SIOPEL 6 phase 3 clinical trial recommended that the study be continued as planned. The IDMC has been established to assess any potential concern of an adverse effect of STS on the efficacy of the cisplatin chemotherapy and to review safety according to protocol pre-specified patient numbers. Previously, the IDMC reached similar conclusion after reviewing the safety of 20, 40, 60 and 80 patients and their current recommendation on 100 patients to continue the clinical trial represents the last and final safety review.
FRX.TO: 2.77 (-0.29)

Fennec Pharmaceuticals Announces Completion of Patient Enrollment in Sodium Thiosulfate Phase 3 SIOPEL 6 Study
Marketwired - Mon Jan 05, 8:03AM CST
Fennec Pharmaceuticals Inc. (TSX: FRX)(OTCQB: FENCF), today reported the second sodium thiosulfate Phase 3 study, conducted by the International Childhood Liver Tumour Strategy Group, SIOPEL 6, has fully enrolled and is now closed for recruitment. One hundred and sixteen patients in 46 clinical centers from 12 countries participated in the study.
FRX.TO: 2.77 (-0.29)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

America's Group Adds Swansea to Its UK Auction Map

Updated Category News Views 19

A Welsh Lane Joins a Larger Road Port Talbot just became a small but telling dot on America's Group's international map. The company has acquired Swansea Motor Vehicle Auction Limited, a long-standing South Wales wholesale and remarketing operation, and plans to run it under the G3 brand. This is not the sort of deal that makes markets levitate. It is the sort that tells...

Continue Reading
Mantle's Japan Listing Puts $MNT Through a Real Test

Updated Category News Views 88

Japan's crypto gatekeepers just handed Mantle a key, not a crown. The November 18 listing of $MNT on GMO Coin is a meaningful operational win because getting onto a Japanese centralized exchange is not the usual loose-change exercise seen in friendlier jurisdictions. Mantle cleared a review process involving GMO Coin and the Japan Virtual and Crypto Assets Exchange...

Continue Reading
Xailient Tops NIST for Real-World AI Face Recognition

Updated Category News Views 87

In a world where bigger ain't always better, Xailient's latest triumph at NIST's face recognition test has set them apart. On November 17, 2026, the U.S. National Institute of Standards and Technology (NIST) crowned Xailient as the leader in face recognition accuracy for on-device AI, leaving 105 others in the dust. This ain't your run-of-the-mill achievement—it shows...

Continue Reading
AES Clears FERC, Nearing Its December 2 Takeover Close

Updated Category News Views 119

One more regulatory gate just swung open for AES, and this deal is finally staring at the finish line instead of wandering through the usual approval swamp. The Federal Energy Regulatory Commission has issued its final order approving AES's acquisition by a consortium led by Global Infrastructure Partners, part of BlackRock, and EQT Infrastructure VI. The last major...

Continue Reading
Triple Crossing Tests a Tough Inland Marine Market

Updated Category News Views 150

Inland marine is where tidy insurance appetites go to get bent out of shape. A contractor’s rented machine, cargo moving between points, a half-finished building, or equipment that is neither parked forever nor easy to classify can turn a standard quote into a week of broker phone calls. Triple Crossing Specialty is stepping directly into that mess, launching a new...

Continue Reading
ELEGOO's Formnext Push Tests a Broader 3D Ambition

Updated Category News Views 123

Frankfurt’s show floor is where product promises meet some very unforgiving eyeballs. ELEGOO arrived at Formnext 2026 with more than a refreshed machine or two: it is laying out a wider bet across resin printing, FDM printing, and 3D scanning. That matters because the company is no longer presenting itself as merely a supplier of affordable creator hardware. It wants to...

Continue Reading
Animal Parasite Market Growth Has a Resistance Catch

Updated Category News Views 156

Flea collars and cattle worms do not sound glamorous, yet this is exactly where durable animal-health revenue gets built. Wissen Research puts the global animal parasiticides market at $13.6 billion in 2026 and projects $18.6 billion by 2031, a 6.5% compound annual growth rate. That is respectable, not moonshot stuff, and frankly that is part of the appeal. Pet owners...

Continue Reading
Stitch AI Targets Banking’s Hardest Automation Gap

Updated Category News Views 15

The flashy chatbot stuff is cheap; banking permission to act is not. That is why Stitch AI’s launch deserves more attention than another vendor slapping “agentic” on a slide deck and calling it transformation. Banks do not need a machine to summarize a policy document while everyone applauds the demo. They need technology that can touch real workflows without...

Continue Reading
Dolby's Strong Quarter Meets a Flat 2027 Reality Check

Updated Category News Views 81

A licensing machine just coughed up a very good quarter, then told investors not to expect the engine to accelerate next year. That is the whole Dolby story in one uncomfortable breath. NYSE:DLB finished fiscal 2026 with fourth-quarter revenue of $374 million, up from $307 million a year earlier, while GAAP diluted earnings climbed to $0.86 from $0.51. Those are not...

Continue Reading
Thoughts Unleashed Arrives With a Personal American Voice

Updated Category News Views 114

A lifetime of observation finally gets its own page Forty is an unusual age to begin writing poetry, which is exactly why Joyce Ann Grooms McGeehan's debut has a little more texture than the usual polished promise of inspiration. Thoughts Unleashed by an Independent, American Woman comes from someone who spent decades teaching French, English, and ESL, then retired to a...

Continue Reading

Top 5 Most Recently Viewed Articles

Exciting Changes in Leadership Position at ibex Limited

Updated Category News Views 289

Board of Directors' Transformation at ibex Limited ibex Limited, a prominent player in global business process outsourcing, has recently made significant changes to its Board of Directors. The company announced that Gerard Kleisterlee will retire from his position after the upcoming Annual General Meeting (AGM). A Fond Farewell to Gerard Kleisterlee Gerard has been an...

Continue Reading
Umicore's Shareholding Update: Impact and Insights

Updated Category News Views 148

Investor Transparency Notification from Silchester International Investors LLP Transparency notification by Silchester International Investors LLP Umicore has recently received a significant transparency notification regarding shareholding changes from Silchester International Investors LLP. This notification falls under the legal obligations concerning major holdings as...

Continue Reading
Exploring the Future of Retail at Digital Retail Africa 2025

Updated Category News Views 212

Event Overview of Digital Retail Africa 2025 The retail landscape is experiencing significant change, and Digital Retail Africa 2025 aims to prepare businesses for the rapidly evolving challenges and opportunities that lie ahead. This influential event, scheduled for January 30, 2025, at a premier venue, will gather top industry professionals, innovators, and...

Continue Reading
Understanding the Impact of Wegovy's Medicare Negotiation

Updated Category News Views 362

Implications of Wegovy's Medicare Price Negotiation The recent announcement regarding Medicare's negotiations for prescription medications has sparked considerable interest, particularly with the inclusion of Novo Nordisk's (NYSE: NVO) groundbreaking weight-loss drug, Wegovy. This decision marks a significant moment for both healthcare providers and patients across the...

Continue Reading
Max Stock Ltd. Receives Resignation News from Deputy CEO

Updated Category News Views 289

Max Stock Ltd. Announces Resignation of Deputy CEO Max Stock Limited (TASE: MAXO) has revealed that Mr. Nir Dagan, the Company’s Deputy CEO and Head of Finance, has decided to resign after nine impactful years of service. Mr. Dagan will remain in his position until the end of the calendar year. The Company appreciates Mr. Dagan’s extensive contribution over the years,...

Continue Reading